Cowen Downgrades Aegerion Pharmaceuticals (AEGR) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
Aegerion (AEGR) Q1 Juxtapid Sales 'Surprisingly Weak', Jefferies Says
May 7, 2014 9:00 AM EDTJefferies analyst Eun K. Yang, Ph.D lowered his price target on Buy-rated Aegerion Pharmaceuticals (NASDAQ: AEGR) to $61.00 (from $80.00) following 'surprisingly' weak Q1 Juxtapid sales.
Yang comments, "While AEGR is confident of meeting its ~5% lowered guidance ($180M-$200M), surprisingly weak 1Q14 Juxtapid... More
Aegerion (AEGR) PT Lowered to $70 at Deutsche Bank Due to Slow Patient Growth
May 7, 2014 8:37 AM EDTDeutsche Bank maintained a Buy rating on Aegerion Pharmaceuticals (NASDAQ: AEGR) an reduced its price target to $70.00 (from $115.00). Analyst Robyn Karnauskas expressed caution due to slow patient growth.
"Juxtapid 1Q revenues at $27M were lower than consensus at $33.6M primarily due to lower sales in ex-US.... More
Aegerion Pharmaceuticals, Inc. (AEGR) Tops Q1 EPS by 10c
May 6, 2014 4:34 PM EDTAegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) reported Q1 EPS of ($0.25), $0.10 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $27 million versus the consensus estimate of $33.58 million.
Highlights
Aegerion achieved $27.0 million in net product sales of JUXTAPID® (lomitapide) capsules in the first-quarter of 2014. 96% of net product sales in the first quarter were from the United States business, representing growth of 24% over net product sales from the U.S. business in the prior quarter. The Company now expects to achieve between $180 million and $200 million of net product sales... More